Table 1

Summary of the clinical and histological data of 18 patients with primary and recurrent gliomas

Case

Age (y)

Sex

Site of tumor

Interval of biopsies (m)

Survival (m)

Histology P/R

Adjuvant therapy

1

20

M

RTL

15

ALIVE

PA2

R

RTL

RA3

-

2

48

M

LTL

24

ALIVE

PA2

R

LTL

RA3

-

3

55

M

RFL

13

14

PA3

-

RFL

RA3

-

4

50

F

LTL

74

ALIVE

PA2

R

LTL

RA3

T

5

30

M

RFL

662

ALIVE

PA2

R

RFL

RA3

-

6

41

F

RTL

42

64

PA2

R

RTL

RA3

-

7

50

M

LOL

9

18

PA3

R

LOL

RGB

T

8

15

F

LFL

31

49

PA3

R

LFL

RGB

CVP

9

27

F

RFL

33

98

PA3

R

RFL

RGB

T

10

56

F

RPL

12

32

PA3

R

RPL

RGB

-

11

69

F

RFL

11

16

PGB

R

RFL

RGB

-

12

44

M

LPL

3

6

PGB

R

LPL

RGB

-

13

47

M

LFL

9

12

PGB

-

LFL

RGB

T

14

55

M

LTL

13

19

PGB

R

LTL

RGB

T

15

62

M

RFL

6

18

PGB

R

RFL

RGB

T

16

54

M

RTL

12

14

PGB

R

RTL

RGB

T

17

41

M

RTL

10

24

PGCGB

R

RTL

RGCGB

T

18

17

F

RTL

15

29

PGCGB

R

RTL

RGCGB

CVP

Abbreviations: Histology: P for primary and R for recurrence; A2, diffuse astrocytoma; A3, anaplastic astrocytoma; GB, glioblastoma; GCGB, giant cell glioblastoma; LFL, left frontal lobe; RFL, right frontal lobe; LTL, left temporal lobe; RTL, right temporal lobe; RPL, right parietal lobe; ROL, right occipital lobe; R, radiotherapy; CVP, Carbo/VP-16 chemotherapy; T, Temodal; female; M, male; y, year; m, month; Interval is the time in months between the two biopsies

Gömöri et al. Diagnostic Pathology 2012 7:8   doi:10.1186/1746-1596-7-8